Surface Oncology Yönetim

Yönetim kriter kontrolleri 3/4

Surface Oncology CEO'su Rob Ross, Apr2021 tarihinde atandı, in görev süresi 2.42 yıldır. in toplam yıllık tazminatı $ 1.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 29.5% maaş ve 70.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.14% ine doğrudan sahiptir ve bu hisseler € 83.21K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 4.7 yıldır.

Anahtar bilgiler

Rob Ross

İcra Kurulu Başkanı

US$1.9m

Toplam tazminat

CEO maaş yüzdesi	29.5%
CEO görev süresi	2.4yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	4.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Rob Ross'un ücretlendirmesi Surface Oncology'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2023	n/a	n/a	-US$93m
Mar 31 2023	n/a	n/a	-US$90m
Dec 31 2022	US$2m	US$568k	-US$64m
Sep 30 2022	n/a	n/a	-US$66m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$57m
Dec 31 2021	US$5m	US$506k	-US$78m
Sep 30 2021	n/a	n/a	US$13m
Jun 30 2021	n/a	n/a	US$17m
Mar 31 2021	n/a	n/a	US$21m
Dec 31 2020	US$1m	US$435k	US$59m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$25m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$810k	US$400k	-US$55m
Sep 30 2019	n/a	n/a	-US$44m
Jun 30 2019	n/a	n/a	-US$44m
Mar 31 2019	n/a	n/a	-US$35m
Dec 31 2018	US$880k	US$361k	-US$7m
Sep 30 2018	n/a	n/a	-US$18m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$467k	US$329k	-US$45m

Tazminat ve Piyasa: Rob 'nin toplam tazminatı ($USD 1.92M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 474.54K ).

Tazminat ve Kazançlar: Rob 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Rob Ross (49 yo)

2.4yrs

Görev süresi

US$1,924,455

Tazminat

Dr. Robert W. Ross, also known as Rob, M.D., is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Independent Director at Xilio Therapeutics, Inc....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Ross	President	2.4yrs	US$1.92m	0.14% € 83.2k
Alison O'Neill	Chief Medical Officer	3.6yrs	US$1.06m	Veri yok
Jessica Fees	CFO & Treasurer	4.8yrs	Veri yok	0.17% € 101.9k
Chandra Adams	Deputy General Counsel & Secretary	less than a year	Veri yok	0.051% € 30.9k
Lisa McGrath	Chief People Officer	no data	Veri yok	Veri yok
Shannon Devens	Senior Vice President of Development Operations	1.8yrs	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: QSOA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Ross	President	2.4yrs	US$1.92m	0.14% € 83.2k
Charles Sigal	Independent Member of Scientific Advisory Board & Director	5.6yrs	US$80.57k	0.075% € 45.5k
David Grayzel	Independent Director	9.4yrs	US$84.57k	0% € 0
J. Goater	Director	5.6yrs	US$72.57k	0.21% € 129.2k
Alexander Rudensky	Member of Scientific Advisory Board	4.7yrs	Veri yok	Veri yok
Armen Shanafelt	Independent Director	8.8yrs	US$89.07k	0% € 0
Laurie Stelzer	Independent Director	5.6yrs	US$92.57k	0% € 0
F. Hodi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Denice Torres	Independent Chairman & Lead Independent Director	2.2yrs	US$151.82k	0% € 0
Christopher Hunter	Member of Scientific Advisory Board	4.7yrs	Veri yok	Veri yok
Carla Rothlin	Member of Scientific Advisory Board	4.7yrs	Veri yok	Veri yok
Arlene Sharpe	Member of Scientific Advisory Board	4.7yrs	Veri yok	Veri yok

4.7yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: QSOA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).

Surface Oncology Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

Recent updates

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.43 loss in 2Q 2021)

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.37 loss in 1Q 2021)

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

Revenue beats expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

New 90-day low: €5.95

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

New 90-day high: €9.20

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

New 90-day high: €8.75

Surface Oncology, Inc. Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer

Revenue in line with expectations

Surface Oncology to Present Srf388 and Srf114 Preclinical Data At the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference

Surface Oncology, Inc. Announces Preclinical Data on SRF388

New 90-day high: €6.05

New 90-day high - €5.95

Earnings released

Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş